<p>Innovate Corporation announced that MediBeacon Inc., in which Innovate holds a 44.7% equity interest, has received FDA approval for the next generation MediBeacon® TGFR™ System, including the latest TGFR™ Reusable Sensor. This first-in-kind device enables point-of-care kidney function assessment using transdermal GFR technology. Initial commercialization at select academic medical centers in the United States and China is expected to begin in early 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovate Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9602760) on December 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

VATE RT

VATE

<p>Innovate Corporation announced that MediBeacon Inc., in which it holds a 44.7% equity interest, has received FDA approval for the MediBeacon TGFR System, a device for point-of-care kidney function assessment. Initial commercialization is expected in early 2026 in the US and China.</p>

Innovate Corporation's MediBeacon TGFR System Wins FDA Approval